Endocare ENDO
-
Buckingham says Watson Pharmaceuticals ([[WPI]] -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo ([[ENDP]] ...
… remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo ( ENDP -0.8% ). The firm reiterates its Buy rating with a $100 price target. Post your comment!
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… s success. Such hard-to-manufacture products, including Watson's near-term opportunity with a generic version of Endo 's ENDP Lidoderm, help sustain above-average growth and profitability when compared with conventional small molecule drugs …
-
Can Teva Win With The Big Pharma Playbook?
… SNY ) are in generics, and generic companies like Teva are in branded drugs. And just for good measure, a few outliers like Endo Pharmaceuticals ( ENDP ) add devices to the mix, while others like Abbott ( ABT ) and Covidien ( COV ) look to split and spin …
-
Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Endo Pharmaceuticals Holdings Inc. ( ENDP ) Q1 2012 Earnings Call May 1, 2012 9:00 ..... Presentation Operator Good day, ladies and gentlemen, and welcome to the Q1 2012 Endo Pharmaceuticals Earnings Conference Call. (Operator Instructions) I’d now …
-
Near-Term Supply Issues and Generic Threats Weigh on Endo in 1Q
Endo Pharmaceuticals ENDP reported stagnant first ..... AMS added $130 million in device revenue to Endo 's top line during the quarter, and services ..... 1.00 in first-quarter 2011. We expect Endo to return to earnings growth for the rest …
-
Endo Pharmaceuticals (ENDP): Q1 EPS of $0.87 beats by $0.01. Revenue of $691M (+23.3% Y/Y) misses by $9M. (PR)
Endo Pharmaceuticals ( ENDP ): Q1 EPS of $0.87 beats by $0.01 . Revenue of $691M (+23.3% Y/Y) misses by $9M . ( PR ) Post your comment!
-
New Morningstar Analyst Report - Johnson & Johnson
… in 40% of sales, with the company holding controlling positions in many areas, including DePuy's orthopedics and Ethicon Endo -Surgery's surgical devices. The pending acquisition of Synthes SYST will further the company's leading position in the …
-
BioDelivery's Spike May Be A Short-Lived Downer
… into these low-flyers like the old story of the 'spider and the fly'. Granted, BioDelivery signed a promising deal with Endo Pharma, but just in time since the company's cash position was anemic. My worry is the technical chart. The RSI is about …
-
Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business
… Covidien's pharma unit isn't facing major business disruptions like some of its peers, such as Lidoderm's patent loss for Endo ENDP, Cardiolite's patent loss for the former Bristol BMY imaging business, loss of Provigil for Cephalon (now part of Teva …
-
BioDelivery Sciences: A Case Of Two Steps Forward, One Step Back?
… company signed a worldwide licensing and development agreement with Endo Pharmaceuticals ( ENDP ) to bring BEMA Buprenorphine to market ..... The recently-announced licensing deal is an indicator that Endo agrees with that assessment. BioDelivery received additional …